WO2007044411A3 - Anti-myostatin antibodies - Google Patents

Anti-myostatin antibodies Download PDF

Info

Publication number
WO2007044411A3
WO2007044411A3 PCT/US2006/038818 US2006038818W WO2007044411A3 WO 2007044411 A3 WO2007044411 A3 WO 2007044411A3 US 2006038818 W US2006038818 W US 2006038818W WO 2007044411 A3 WO2007044411 A3 WO 2007044411A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies
gdf
epitope
bind
myostatin antibodies
Prior art date
Application number
PCT/US2006/038818
Other languages
French (fr)
Other versions
WO2007044411A2 (en
Inventor
Bomie Han
Andrew Korytko
Pamela Jean Mitchell
Rosamund Carol Smith
Nee Tobias Linda O'bryan
Rong Wang
Original Assignee
Lilly Co Eli
Bomie Han
Andrew Korytko
Pamela Jean Mitchell
Rosamund Carol Smith
Nee Tobias Linda O'bryan
Rong Wang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BRPI0616923-6A priority Critical patent/BRPI0616923A2/en
Priority to EA200801027A priority patent/EA015589B1/en
Priority to JP2008534657A priority patent/JP5052517B2/en
Priority to US12/066,664 priority patent/US7635760B2/en
Application filed by Lilly Co Eli, Bomie Han, Andrew Korytko, Pamela Jean Mitchell, Rosamund Carol Smith, Nee Tobias Linda O'bryan, Rong Wang filed Critical Lilly Co Eli
Priority to KR1020087008254A priority patent/KR101135220B1/en
Priority to CA002624976A priority patent/CA2624976A1/en
Priority to CN2006800368248A priority patent/CN101277976B/en
Priority to ES06816226.2T priority patent/ES2533464T3/en
Priority to AU2006302494A priority patent/AU2006302494B2/en
Priority to EP06816226.2A priority patent/EP1951756B1/en
Publication of WO2007044411A2 publication Critical patent/WO2007044411A2/en
Publication of WO2007044411A3 publication Critical patent/WO2007044411A3/en
Priority to IL189579A priority patent/IL189579A0/en
Priority to NO20082073A priority patent/NO20082073L/en
Priority to US12/612,060 priority patent/US7745583B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Abstract

A neutralizing epitope is identified within amino acids 40-64 of the mature form of human myostatin. Antibodies that bind this epitope with high affinity preferentially bind GDF-8 over GDF-11 and may be chimeric, humanized or fully human antibodies, immunoconjugates of the antibodies or antigen-binding fragments thereof. The antibodies of the invention are useful for increasing muscle mass, increasing bone density, or for the treatment of various disorders in mammalian and avian species.
PCT/US2006/038818 2005-10-06 2006-10-05 Anti-myostatin antibodies WO2007044411A2 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
CA002624976A CA2624976A1 (en) 2005-10-06 2006-10-05 Anti-myostatin antibodies
JP2008534657A JP5052517B2 (en) 2005-10-06 2006-10-05 Anti-myostatin antibody
US12/066,664 US7635760B2 (en) 2005-10-06 2006-10-05 Anti-myostatin antibodies
ES06816226.2T ES2533464T3 (en) 2005-10-06 2006-10-05 Anti-myostatin antibodies
KR1020087008254A KR101135220B1 (en) 2005-10-06 2006-10-05 Anti-myostatin antibodies
EA200801027A EA015589B1 (en) 2005-10-06 2006-10-05 Anti-myostatin antibodies and the use thereof
CN2006800368248A CN101277976B (en) 2005-10-06 2006-10-05 Anti-myostatin antibodies
BRPI0616923-6A BRPI0616923A2 (en) 2005-10-06 2006-10-05 monoclonal antibodies, their uses and pharmaceutical composition
AU2006302494A AU2006302494B2 (en) 2005-10-06 2006-10-05 Anti-myostatin antibodies
EP06816226.2A EP1951756B1 (en) 2005-10-06 2006-10-05 Anti-myostatin antibodies
IL189579A IL189579A0 (en) 2005-10-06 2008-02-18 Anti-myostatin antibodies
NO20082073A NO20082073L (en) 2005-10-06 2008-05-02 Anti-myostatin antibodies
US12/612,060 US7745583B2 (en) 2005-10-06 2009-11-04 Anti-myostatin antibodies

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US72467005P 2005-10-06 2005-10-06
US60/724,670 2005-10-06
US72523505P 2005-10-11 2005-10-11
US60/725,235 2005-10-11
US72606205P 2005-10-12 2005-10-12
US60/726,062 2005-10-12

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/066,664 A-371-Of-International US7635760B2 (en) 2005-10-06 2006-10-05 Anti-myostatin antibodies
US12/612,060 Continuation US7745583B2 (en) 2005-10-06 2009-11-04 Anti-myostatin antibodies

Publications (2)

Publication Number Publication Date
WO2007044411A2 WO2007044411A2 (en) 2007-04-19
WO2007044411A3 true WO2007044411A3 (en) 2007-08-16

Family

ID=37943347

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/038818 WO2007044411A2 (en) 2005-10-06 2006-10-05 Anti-myostatin antibodies

Country Status (13)

Country Link
US (2) US7635760B2 (en)
EP (1) EP1951756B1 (en)
JP (1) JP5052517B2 (en)
KR (1) KR101135220B1 (en)
CN (1) CN101277976B (en)
AU (1) AU2006302494B2 (en)
BR (1) BRPI0616923A2 (en)
CA (1) CA2624976A1 (en)
EA (1) EA015589B1 (en)
ES (1) ES2533464T3 (en)
IL (1) IL189579A0 (en)
NO (1) NO20082073L (en)
WO (1) WO2007044411A2 (en)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1951756B1 (en) 2005-10-06 2015-01-07 Eli Lilly And Company Anti-myostatin antibodies
UA92504C2 (en) 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
DK3056568T3 (en) 2006-03-31 2021-11-01 Chugai Pharmaceutical Co Ltd PROCEDURES FOR CONTROL OF THE BLOOD PHARMACOKINETICS OF ANTIBODIES
KR101123531B1 (en) * 2006-09-05 2012-04-20 일라이 릴리 앤드 캄파니 Anti-myostatin antibodies
EP3002009B1 (en) 2007-06-01 2021-07-07 Wyeth LLC Treatment of imatinib resistant chronic myelogenous leukemia having the mutaton 1457t>c in the bcrabl gene using the compound bosutinib
JP5334319B2 (en) 2007-09-26 2013-11-06 中外製薬株式会社 Method for modifying isoelectric point of antibody by amino acid substitution of CDR
KR100857861B1 (en) * 2007-10-15 2008-09-11 주식회사 바이오리더스 Surface expression vector for fusion protein of myo-2 peptide multimer and myostatin, and microorganism transformed by therof
PE20091163A1 (en) * 2007-11-01 2009-08-09 Wyeth Corp ANTIBODIES FOR GDF8
CA2721052C (en) 2008-04-11 2023-02-21 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
CA2735193A1 (en) * 2008-08-26 2010-03-11 Macrogenics, Inc. T-cell receptor antibodies and methods of use thereof
AR074777A1 (en) 2008-12-19 2011-02-09 Glaxo Group Ltd PROTEINS OF UNION TO ANTIGEN
JO3340B1 (en) 2010-05-26 2019-03-13 Regeneron Pharma Antibodies to human gdf8
AR081556A1 (en) 2010-06-03 2012-10-03 Glaxo Group Ltd HUMANIZED ANTIGEN UNION PROTEINS
CN103221426B (en) 2010-08-16 2016-01-13 安姆根公司 In conjunction with the antibody of myostatin, composition and method
AR082641A1 (en) 2010-09-07 2012-12-19 Imclone Llc ANTI-VEGFR-3 ANTIBODY COMPOSITIONS
SG10201509790YA (en) 2010-11-30 2015-12-30 Chugai Pharmaceutical Co Ltd Antigen-Binding Molecule Capable Of Binding To Plurality Of Antigen Molecules Repeatedly
CN102212545B (en) * 2011-04-07 2013-05-08 北京济福霖生物技术有限公司 Method for knocking out cattle beta-lactoglobulin gene by using zinc finger nucleases (ZFNs)
CN102260711B (en) * 2011-06-24 2013-09-18 北京济福霖生物技术有限公司 Method for knocking out bovine myostatin gene by using zinc finger nuclease
DK2780368T3 (en) 2011-11-14 2018-02-05 Regeneron Pharma COMPOSITIONS AND PROCEDURES FOR INCREASING MUSCLE MASS AND MUSCLE STRENGTH BY SPECIFIC ANTAGONIZATION OF GDF8 AND / OR ACTIVIN A
CN102660577B (en) * 2012-04-18 2013-12-25 山东省农业科学院奶牛研究中心 Method for knocking out beta 6 subunit genes of bovine integrins by utilizing zinc finger nucleases (ZFNs)
JP6501521B2 (en) 2012-08-24 2019-04-17 中外製薬株式会社 FcγRIIb-specific Fc region variant
EP3597747B1 (en) 2012-08-24 2023-03-15 Chugai Seiyaku Kabushiki Kaisha Mouse fcgammarii-specific fc antibody
LT2895503T (en) 2012-09-13 2019-07-25 Bristol-Myers Squibb Company Fibronectin based scaffold domain proteins that bind to myostatin
JPWO2014119634A1 (en) * 2013-01-30 2017-01-26 国立研究開発法人国立精神・神経医療研究センター Muscle increasing agent and pharmaceutical composition containing the same
AU2014250434B2 (en) 2013-04-02 2019-08-08 Chugai Seiyaku Kabushiki Kaisha Fc region variant
SG10201800800YA (en) 2013-05-06 2018-03-28 Scholar Rock Inc Compositions and methods for growth factor modulation
TW201920262A (en) 2013-07-30 2019-06-01 美商再生元醫藥公司 Anti-activin A antibodies and uses thereof
CA2943334A1 (en) 2014-03-19 2015-09-24 Mackay Medical Foundation The Presbyterian Church In Taiwan Mackay Memorial Hospital Immunogenic glycopeptides, composition comprising the glycopeptides and use thereof
EP2960653A1 (en) * 2014-06-24 2015-12-30 Stichting Kwaliteitsgarantie Vleeskalversector Diagnostic kit and method for the identification of the manipulation of muscle mass in a domestic animal
EP3215175A4 (en) 2014-11-06 2018-06-27 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
TWI779010B (en) 2014-12-19 2022-10-01 日商中外製藥股份有限公司 ANTI-MYOSTATIN ANTIBODIES, POLYPEPTIDES CONTAINING VARIANT Fc REGIONs, AND METHODS OF USE
US9969800B2 (en) 2015-02-05 2018-05-15 Chugai Seiyaku Kabushiki Kaisha IL-8 antibodies
AU2016249015B2 (en) 2015-04-15 2022-03-24 Regeneron Pharmaceuticals, Inc. Methods of increasing strength and functionality with GDF8 inhibitors
RS62330B1 (en) 2015-09-15 2021-10-29 Scholar Rock Inc Anti-pro/latent-myostatin antibodies and uses thereof
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
SG11201801024XA (en) 2016-08-05 2018-05-30 Chugai Pharmaceutical Co Ltd Therapeutic or preventive compositions for il-8-related diseases
HRP20230308T1 (en) 2017-01-06 2023-05-12 Scholar Rock, Inc. Treating metabolic diseases by inhibiting myostatin activation
WO2018162931A1 (en) * 2017-03-10 2018-09-13 Ucl Business Plc Method relating to myostatin pathway inhibition
WO2019169283A1 (en) 2018-03-01 2019-09-06 Regeneron Pharmaceuticals, Inc. Methods for altering body composition
EP3898672A1 (en) 2018-12-18 2021-10-27 Regeneron Pharmaceuticals, Inc. Compositions and methods for enhancing body weight and lean muscle mass using antagonists against leptin receptor, gdf8 and activin a
WO2024064842A1 (en) 2022-09-21 2024-03-28 Regeneron Pharmaceuticals, Inc. Methods of treating obesity, diabetes, and liver dysfunction

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030138422A1 (en) * 2001-09-26 2003-07-24 Jane Aghajanian Antibody inhibitors of GDF-8 and uses thereof
WO2004037861A2 (en) * 2002-10-22 2004-05-06 Wyeth Neutralizing antibodies against gdf-8 and uses therefor
US20050014733A1 (en) * 2003-06-02 2005-01-20 Lisa-Anne Whittemore Therapeutic and prophylactic methods for neuromuscular disorders
WO2005094446A2 (en) * 2004-03-23 2005-10-13 Eli Lilly And Company Anti-myostatin antibodies
WO2006116269A2 (en) * 2005-04-25 2006-11-02 Pfizer Inc. Antibodies to myostatin
WO2007024535A2 (en) * 2005-08-19 2007-03-01 Wyeth Antagonist antibodies against gdf-8 and uses in treatment of als and other gdf-8-associated disorders
WO2007047112A2 (en) * 2005-10-12 2007-04-26 Eli Lilly And Company Anti-myostatin antibodies

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7393682B1 (en) * 1993-03-19 2008-07-01 The Johns Hopkins University School Of Medicine Polynucleotides encoding promyostatin polypeptides
US5994618A (en) 1997-02-05 1999-11-30 Johns Hopkins University School Of Medicine Growth differentiation factor-8 transgenic mice
EP0690873B1 (en) * 1993-03-19 2003-06-11 The Johns Hopkins University School Of Medicine Growth differentiation factor-8
KR100227406B1 (en) * 1993-05-12 1999-12-01 브루스 엠. 에이센 Bmp-11 composition
WO1996001845A1 (en) 1994-07-08 1996-01-25 The Johns Hopkins University School Of Medicine Growth differentiation factor-11
US6008434A (en) 1994-07-08 1999-12-28 Johns Hopkins University School Of Medicine Growth differentiation factor-11 transgenic mice
WO1999006559A1 (en) 1997-08-01 1999-02-11 The Johns Hopkins University School Of Medicine Methods to identify growth differentiation factor (gdf) receptors
US6656475B1 (en) 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
US6696260B1 (en) 1997-08-01 2004-02-24 The Johns Hopkins University School Of Medicine Methods to identify growth differentiation factor (GDF) binding proteins
AU1276399A (en) 1997-11-07 1999-05-31 Genetics Institute Inc. Neuronal uses of bmp-11
GB2333706A (en) 1998-02-02 1999-08-04 Merck & Co Inc Method for increasing muscle mass in animals
WO1999040181A1 (en) 1998-02-05 1999-08-12 The Johns Hopkins University School Of Medicine Growth differentiation factor-8
ES2330062T3 (en) 1998-05-06 2009-12-03 Metamorphix, Inc. PROCEDURES TO TREAT DIABETES FOR INHIBITION OF GDF-8.
US7504490B1 (en) * 1998-10-16 2009-03-17 Oscient Pharmaceuticals Corporation Nucleic acid and amino acid sequences relating to Apergillus fumigatus for diagnostics and therapeutics
JP2003517580A (en) 1999-01-21 2003-05-27 メタモーフイクス・インコーポレーテツド Growth differentiation factor inhibitors and their uses
CA2498044A1 (en) 2002-09-16 2004-03-25 Wyeth Metalloprotease activation of myostatin, and methods of modulating myostatin activity
PT1581649E (en) * 2002-12-20 2011-04-13 Amgen Inc Binding agents which inhibit myostatin
NZ529860A (en) * 2003-11-28 2006-10-27 Ovita Ltd Muscle growth regulator mighty and use in promoting muscle mass and treating muscle wasting diseases
EP1699820A2 (en) 2003-12-31 2006-09-13 Schering-Plough Ltd. Neutralizing epitope-based growth enhancing vaccine
BRPI0514253A (en) 2004-08-12 2008-06-03 Wyeth Corp combination therapy for diabetes, obesity and cardiovascular disease using compositions containing gdf-8 inhibitors
NZ538097A (en) * 2005-02-07 2006-07-28 Ovita Ltd Method and compositions for improving wound healing
BRPI0609449A2 (en) * 2005-03-23 2010-04-06 Wyeth Corp gdf-8 modulation agent detection
US20090215671A1 (en) * 2005-05-27 2009-08-27 The Regents Of The University Of California Compositions And Methods For Treatment of Neural Disorders Using Transforming Growth Factor-Beta Superfamily Proteins And Their Antagonists
EP1951756B1 (en) * 2005-10-06 2015-01-07 Eli Lilly And Company Anti-myostatin antibodies
WO2007067616A2 (en) * 2005-12-06 2007-06-14 Amgen Inc Uses of myostatin antagonists
US20070190056A1 (en) * 2006-02-07 2007-08-16 Ravi Kambadur Muscle regeneration compositions and uses therefor
KR101123531B1 (en) 2006-09-05 2012-04-20 일라이 릴리 앤드 캄파니 Anti-myostatin antibodies
TWI573802B (en) 2007-03-06 2017-03-11 安美基公司 Variant activin receptor polypeptides and uses thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030138422A1 (en) * 2001-09-26 2003-07-24 Jane Aghajanian Antibody inhibitors of GDF-8 and uses thereof
WO2004037861A2 (en) * 2002-10-22 2004-05-06 Wyeth Neutralizing antibodies against gdf-8 and uses therefor
US20050014733A1 (en) * 2003-06-02 2005-01-20 Lisa-Anne Whittemore Therapeutic and prophylactic methods for neuromuscular disorders
WO2005094446A2 (en) * 2004-03-23 2005-10-13 Eli Lilly And Company Anti-myostatin antibodies
WO2006116269A2 (en) * 2005-04-25 2006-11-02 Pfizer Inc. Antibodies to myostatin
WO2007024535A2 (en) * 2005-08-19 2007-03-01 Wyeth Antagonist antibodies against gdf-8 and uses in treatment of als and other gdf-8-associated disorders
WO2007047112A2 (en) * 2005-10-12 2007-04-26 Eli Lilly And Company Anti-myostatin antibodies

Also Published As

Publication number Publication date
US7745583B2 (en) 2010-06-29
KR101135220B1 (en) 2012-04-24
KR20080045733A (en) 2008-05-23
AU2006302494B2 (en) 2011-01-06
EP1951756A2 (en) 2008-08-06
US20080299126A1 (en) 2008-12-04
BRPI0616923A2 (en) 2011-07-05
US7635760B2 (en) 2009-12-22
JP2009511480A (en) 2009-03-19
NO20082073L (en) 2008-06-17
IL189579A0 (en) 2008-08-07
JP5052517B2 (en) 2012-10-17
CA2624976A1 (en) 2007-04-19
ES2533464T3 (en) 2015-04-10
EA200801027A1 (en) 2008-10-30
US20100087631A1 (en) 2010-04-08
EA015589B1 (en) 2011-10-31
CN101277976B (en) 2012-04-11
CN101277976A (en) 2008-10-01
AU2006302494A1 (en) 2007-04-19
WO2007044411A2 (en) 2007-04-19
EP1951756B1 (en) 2015-01-07

Similar Documents

Publication Publication Date Title
WO2007044411A3 (en) Anti-myostatin antibodies
WO2005094446A3 (en) Anti-myostatin antibodies
WO2007047112A3 (en) Anti-myostatin antibodies
WO2008030706A3 (en) Anti-myostatin antibodies
WO2016081746A3 (en) Antibodies comprising modified heavy constant regions
WO2008115732A3 (en) Anti-sclerostin antibodies
MX2019013132A (en) Antibodies comprising modified heavy constant regions.
WO2017062672A3 (en) Anti-trem2 antibodies and methods of use thereof
NZ595235A (en) Compositions and methods for increasing muscle growth
MY145042A (en) Humanized monoclonal antibodies to hepatocyte growth factor
WO2006138729A3 (en) Receptor antagonists for treatment of metastatic bone cancer
NZ597996A (en) Antibodies against human respiratory syncytial virus (rsv) and methods of use
NZ715896A (en) Humanized or chimeric cd3 antibodies
NZ623319A (en) Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
WO2007113172A3 (en) Antibodies against amyloid-beta peptide
WO2013106485A3 (en) Ultralong complementarity determining regions and uses thereof
WO2010054265A3 (en) Monoclonal antibodies to fibroblast growth factor receptor 2
HK1094167A1 (en) Monoclonal antibodies to hepatocyte growth factor
JP2016094424A5 (en)
WO2021203030A3 (en) Methods of use of anti-trem2 antibodies
WO2008100563A3 (en) Compositions and methods for diagnosing and treating cancer
EP4276108A3 (en) Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies
WO2005014653A3 (en) Humanized chicken antibodies
RU2019100222A (en) ANTIBODIES TO C5 AND METHODS OF THEIR APPLICATION
UA95457C2 (en) Anti-myostatin monoclonal antibody

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680036824.8

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 189579

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 12066664

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2008534657

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2624976

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/004565

Country of ref document: MX

Ref document number: 2006302494

Country of ref document: AU

Ref document number: 2809/DELNP/2008

Country of ref document: IN

Ref document number: 1020087008254

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006816226

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006302494

Country of ref document: AU

Date of ref document: 20061005

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 200801027

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: a200802966

Country of ref document: UA

ENP Entry into the national phase

Ref document number: PI0616923

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080404